logo
logo

Aria CV Announces $31 Million in Series B Funding

Feb 25, 2020•over 5 years ago

Amount Raised

$31 Million

Round Type

series b

St. Paul

Description

Aria CV, Inc., a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that it has completed a $31 million Series B round of financing to fund its first clinical study in the United States. The financing was led by Xeraya Capital, a private equity and venture investor in life sciences that focuses on medical technologies, healthcare biotechnology, and bio-renewables. Also participating in the financing were Longview Ventures, Catalyst Health Ventures, BioStar Ventures, Cedar Point Capital, Frontcourt Group, and three strategic investors.

Company Information

Company

Aria Cv

Location

St. Paul, Minnesota, United States

About

Based in St. Paul, Minnesota, Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, following development work the two had done at the University of Minnesota’s Earl E. Bakken Medical Devices Center. Aria has performed a successful acute first in human clinical study in Vienna, Austria and is now preparing for a U.S. clinical trial under the FDA’s Early Feasibility Study Program to evaluate long term implants in PAH patients.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People